Page 102 - 2018_11-Haematologica-web

N. Takahaski et al. References
1. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treat- ment of patients with newly diagnosed chronic phase, Philadelphia chromosome- positive, chronic myeloid leukaemia: 24- month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841–851.
2. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromo- some-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197–2203.
3. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054.
4. Hughes TP, Lipton JH, Spector N, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124(5):729–736.
5. Hughes TP, Ross DM. Moving treatment- free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23.
6. Dulucq S, Mahon FX. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. 2016;5(9):2398–2411.
7. Rea D, Cayuela JM. Treatment-free remis- sion in patients with chronic myeloid leukemia. Int J Hematol 2017 Jul 8. [Epub ahead of print]
8. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multi- centre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035.
9. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable
minimal residual disease: results from the
TWISTER study. Blood. 2013;122:515–522. 10. Etienne G, Guilhot J, Rea D, et al. Long- term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;
35(3):298–305.
11. Imagawa J, Tanaka H, Okada M, et al.
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicen- tre phase 2 trial. Lancet Haematol. 2015;2(12):e528–535.
with imatinib--a dream come true? Nat Rev
Clin Oncol. 2011;8(3):127–128.
19. Takahashi N. Predictive factors of success-
ful treatment-free remission for patients with chronic myeloid leukemia. Rinsho Ketsueki. 2014;55(5):489–496.
20. Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remis- sion in chronic myeloid leukemia. Leukemia. 2016;30(8):1638–1647.
21. Mahon FX, Boquimpani C, Kim DW, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168(7):461-
12. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following front-
line nilotinib in patients with chronic 470.
myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525–1531.
13. Noguchi S, Nakaseko C, Nishiwaki K, et al. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. Int J Hematol. 2018;108(2):176-183.
14. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97(6):903–906.
15. Mahon F, Richter J, Guilhot J, et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski trial. Blood. 2016;128(22):787.
16. Mori S, Vegge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910–914.
17. Takahashi N, Tauchi T, Kitamura K, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107(2):185–193.
18. Deininger M. Hematology: curing CML
22. Mizoguchi I, Yoshimoto T, Katagiri S, et al. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. Cancer Sci. 2013;104(9):1146–1153.
23. Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108– 1116.
24. Richter J, Soderlund S, Lubking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinu- ation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32(25):2821–2823.
25. Rousselot P, Charbonnier A, Cony- Makhoul P, et al. Reply to J. Richter et al. J Clin Oncol. 2014;32(25):2823–2825.
26. Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment dis- continuation: the KID study. Haematologica. 2016;101(6):717–723.
27. Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57(6):1300–1310.
1842
haematologica | 2018; 103(11)